Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514895 | 0.79 | PPARG (0.43) | PPARGPPARAL3MBTL1KMT2ATDP1 | |
| SCHEMBL4550641 | 0.78 | PPARA (0.54) | PPARGPPARALTA4HHDAC3 | |
| SCHEMBL5508342 | 0.74 | PPARA (0.46) | PPARGPPARALTA4H | |
| SCHEMBL18140326 | 0.74 | PPARG (0.40) | PPARGPPARAL3MBTL1KMT2ATDP1 | |
| SCHEMBL6258633 | 0.74 | PPARG (0.40) | PPARGPPARAL3MBTL1KMT2ATDP1 | |
| SCHEMBL31339000 | 0.74 | PPARG (0.48) | PPARGPPARAL3MBTL1KMT2ATDP1 | |
| SCHEMBL4756797 | 0.73 | PPARG (0.48) | PPARGPPARAALDH1A1 | |
| SCHEMBL3966243 | 0.73 | PPARA (0.52) | PPARGPPARALTA4H | |
| SCHEMBL28826330 | 0.73 | PPARG (0.48) | PPARGPPARAALDH1A1 | |
| SCHEMBL28049678 | 0.73 | PPARG (0.48) | PPARGPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024211384-A1 | EGG BASED MICROCARRIERS AND SCAFFOLDS FOR CELLULAR AGRICULTURE AND OTHER APPLICATIONS | HATCHLESS INC. (US) | 2024-10-10 | — | — | WO | claimed |
| US-20220195392-A1 | METHODS AND COMPOSITIONS FOR CELL CULTURE ON HETEROGENEOUS SCAFFOLDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-23 | — | — | US | claimed |
| EP-3959303-A1 | METHODS AND COMPOSITIONS FOR CELL CULTURE ON HETEROGENEOUS SCAFFOLDS | The Regents of the University of California (US) | 2022-03-02 | — | — | EP | claimed |
| JP-4818905-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| US-20060263335-A1 | Porous matrix | REGENTEC LTD. (GB) | 2006-11-23 | — | — | US | claimed |
| JP-2006521144-A | — | — | 2006-09-21 | — | — | JP | claimed |
| EP-1605984-A1 | POROUS MATRIX | Regentec Ltd (GB) | 2005-12-21 | — | — | EP | claimed |
| WO-2004084968-A1 | POROUS MATRIX | REGENTEC LTD (GB) | 2004-10-07 | — | — | WO | claimed |
| EP-1401400-A1 | POROUS MATRIX COMPRISING CROSS-LINKED PARTICLES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2004-03-31 | — | — | EP | claimed |
| WO-2003000234-A1 | POROUS MATRIX COMPRISING CROSS-LINKED PARTICULES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-01-03 | — | — | WO | claimed |
| US-12611467-B2 | APOE gene therapy | CORNELL UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2025120041-A1 | AGENT TO TREAT A PRIMARY BRAIN TUMOR AND/OR PREVENT A PRIMARY BRAIN TUMOR RELAPSE | NASASBIOTECH, S.L. (ES) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025059173-A1 | ADIPOGENIC CELL CULTURE MEDIA | HATCHLESS INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025019797-A2 | SYSTEM AND METHOD FOR LOW-COST STERILIZATION OF LIQUIDS | HATCHLESS INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024226597-A1 | SYSTEM AND METHOD FOR CELLULAR AGRICULTURE AND APPLICATIONS THEREOF | HATCHLESS INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2010004299-A2 | COMPOSITION | CRITICAL PHARMACEUTICALS LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| US-20080241248-A1 | Porous Matrix | REGENTEC LTD. (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20060263335-A1 | Porous matrix | REGENTEC LTD. (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1605984-A1 | POROUS MATRIX | Regentec Ltd (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004084968-A1 | POROUS MATRIX | REGENTEC LTD (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611467-B2 | APOE gene therapy | APOB, APP, PSEN2 | PPARG 4301/4885PPARA 3801/4885L3MBTL1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.